Chimeric Antigen Receptor Construct for Novel Oncology CAR-T Cell Therapy

Smart Immune, a clinical-stage biotechnology company, has recently achieved a major breakthrough by developing an innovative bioproduction method for cultivating T-cell progenitors. Smart Immune is now seeking a Chimeric Antigen Receptor (CAR) construct, that enables precise recognition of tumour antigens, to develop a groundbreaking CAR-T Cell therapy for the treatment of haematological and/or solid tumour malignancies.

Approaches of Interest:

- All mechanisms of action relating to CARs within the oncology field are of interest
- Both conventional CARs (including e.g., single-antigen-target, dual-antigen-target, and multiple-antigen-target CARs) as well as other types of CARs (including e.g., universal, inhibitory, and physiological CARs) are of interest
- All CAR-T Cell generation methods, such as lentiviral transduction

Out of Scope:

- Screening platforms for receptor discovery
- CAR constructs designed to target antigens unrelated to oncology
- Novel CAR-T Cell delivery methods/route of administration

Developmental Stages of Interest:

- Basic research all the way through to clinical approval is within scope
- Research with safety and efficacy data is of highest interest, although opportunities with earlier stages of validation will still be considered as long as there is proof-of-concept

Submission Information

Submission of one page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.